321 related articles for article (PubMed ID: 31819359)
1. Central Serous Chorioretinopathy: Pathogenesis and Management.
Semeraro F; Morescalchi F; Russo A; Gambicorti E; Pilotto A; Parmeggiani F; Bartollino S; Costagliola C
Clin Ophthalmol; 2019; 13():2341-2352. PubMed ID: 31819359
[TBL] [Abstract][Full Text] [Related]
2. Pharmacotherapy of Central Serous Chorioretinopathy: A Review of the Current Treatments.
Iacono P; Toto L; Costanzo E; Varano M; Parravano MC
Curr Pharm Des; 2018; 24(41):4864-4873. PubMed ID: 30674250
[TBL] [Abstract][Full Text] [Related]
3. Current Pharmacological Treatment Options for Central Serous Chorioretinopathy: A Review.
Nicolò M; Desideri LF; Vagge A; Traverso CE
Pharmaceuticals (Basel); 2020 Sep; 13(10):. PubMed ID: 32977380
[TBL] [Abstract][Full Text] [Related]
4. Central Serous Chorioretinopathy Treatments: A Mini Review.
Iacono P; Battaglia Parodi M; Falcomatà B; Bandello F
Ophthalmic Res; 2015; 55(2):76-83. PubMed ID: 26619293
[TBL] [Abstract][Full Text] [Related]
5. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
Matušková V; Vysloužilová D; Uher M
Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091
[TBL] [Abstract][Full Text] [Related]
6. Low-intensity/high-density subthreshold microPulse diode laser for chronic central serous chorioretinopathy.
Malik KJ; Sampat KM; Mansouri A; Steiner JN; Glaser BM
Retina; 2015 Mar; 35(3):532-6. PubMed ID: 25127050
[TBL] [Abstract][Full Text] [Related]
7. Comparing half-dose photodynamic therapy with high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy (the PLACE trial): study protocol for a randomized controlled trial.
Breukink MB; Downes SM; Querques G; van Dijk EHC; den Hollander AI; Blanco-Garavito R; Keunen JEE; Souied EH; MacLaren RE; Hoyng CB; Fauser S; Boon CJF
Trials; 2015 Sep; 16():419. PubMed ID: 26390920
[TBL] [Abstract][Full Text] [Related]
8. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol.
Breukink MB; Mohr JK; Ossewaarde-van Norel A; den Hollander AI; Keunen JE; Hoyng CB; Boon CJ
Acta Ophthalmol; 2016 Mar; 94(2):187-97. PubMed ID: 26670630
[TBL] [Abstract][Full Text] [Related]
9. Current Therapeutic Approaches to Chronic Central Serous Chorioretinopathy.
Gülkaş S; Şahin Ö
Turk J Ophthalmol; 2019 Feb; 49(1):30-39. PubMed ID: 30829023
[TBL] [Abstract][Full Text] [Related]
10. Central serous chorioretinopathy: what we have learnt so far.
Wong KH; Lau KP; Chhablani J; Tao Y; Li Q; Wong IY
Acta Ophthalmol; 2016 Jun; 94(4):321-5. PubMed ID: 26132864
[TBL] [Abstract][Full Text] [Related]
11. Clinical evaluation of neovascular and non-neovascular chronic central serous chorioretinopathy (CSC) diagnosed by swept source optical coherence tomography angiography (SS OCTA).
Sulzbacher F; Schütze C; Burgmüller M; Vécsei-Marlovits PV; Weingessel B
Graefes Arch Clin Exp Ophthalmol; 2019 Aug; 257(8):1581-1590. PubMed ID: 31037488
[TBL] [Abstract][Full Text] [Related]
12. Modified Photodynamic Therapy Treatment of Central Serous Chorioretinopathy.
Putnam CM; Vang SS
Optom Vis Sci; 2016 Jul; 93(7):760-71. PubMed ID: 27058592
[TBL] [Abstract][Full Text] [Related]
13. Comparison of half-dose photodynamic therapy and 689 nm laser treatment in eyes with chronic central serous chorioretinopathy.
Russo A; Turano R; Morescalchi F; Gambicorti E; Cancarini A; Duse S; Costagliola C; Semeraro F
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1141-1148. PubMed ID: 28283732
[TBL] [Abstract][Full Text] [Related]
14. Update on the management of chronic central serous chorioretinopathy.
Moreno-Morillo FJ; Fernández-Vigo JI; Güemes-Villahoz N; Burgos-Blasco B; López-Guajardo L; Donate-López J
Arch Soc Esp Oftalmol (Engl Ed); 2021 May; 96(5):251-264. PubMed ID: 32891458
[TBL] [Abstract][Full Text] [Related]
15. Detection of morphologic alterations by spectral-domain optical coherence tomography before and after half-dose verteporfin photodynamic therapy in chronic central serous chorioretinopathy.
Shinojima A; Kawamura A; Mori R; Fujita K; Yuzawa M
Retina; 2011 Oct; 31(9):1912-20. PubMed ID: 21952105
[TBL] [Abstract][Full Text] [Related]
16. Short-term efficacy of subthreshold micropulse yellow laser (577-nm) photocoagulation for chronic central serous chorioretinopathy.
Kim JY; Park HS; Kim SY
Graefes Arch Clin Exp Ophthalmol; 2015 Dec; 253(12):2129-35. PubMed ID: 25717024
[TBL] [Abstract][Full Text] [Related]
17. Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy.
Gawęcki M; Jaszczuk-Maciejewska A; Jurska-Jaśko A; Kneba M; Grzybowski A
BMC Ophthalmol; 2019 Jul; 19(1):160. PubMed ID: 31345183
[TBL] [Abstract][Full Text] [Related]
18. [Central serous chorioretinopathy (CSC)].
Baraki H; Feltgen N; Roider J; Hoerauf H; Klatt C
Ophthalmologe; 2010 May; 107(5):479-92; quiz 493. PubMed ID: 20454897
[TBL] [Abstract][Full Text] [Related]
19. System review and meta-analysis on photodynamic therapy in central serous chorioretinopathy.
Ma J; Meng N; Xu X; Zhou F; Qu Y
Acta Ophthalmol; 2014 Dec; 92(8):e594-601. PubMed ID: 25042260
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of anti-VEGF medications for central serous chorioretinopathy: a meta-analysis.
Ji S; Wei Y; Chen J; Tang S
Int J Clin Pharm; 2017 Jun; 39(3):514-521. PubMed ID: 28386700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
